[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endovascular-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endovascular-therapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,72,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100633463","phase-3-stratified-blood-pressure-management-after-endovascular-treatment-for-acute-ischemic-stroke-100633463",false,"NCT07527013","Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke","Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke (RESCUE-BP)","RESCUE-BP","Inclusion Criteria:\n\n* Age ≥ 18 years；\n* Clinical diagnosis of acute ischemic stroke caused by anterior circulation large vessel occlusion (internal carotid artery or M1\u002FM2 segment of the middle cerebral artery)；\n* Received EVT (including direct EVT and bridging therapy) within 24 hours of symptom onset；\n* Baseline ASPECTS score ≥ 3；\n* Baseline NIHSS score ≥ 6；\n* Successful recanalization achieved post-procedure (defined as expanded Thrombolysis in Cerebral Infarction \\[eTICI\\] grade ≥ 2b50);\n* Two consecutive systolic blood pressure (SBP) measurements ≥ 150 mmHg within 3 hours post-recanalization (with a measurement interval of no less than 5 minutes)；\n* Able to complete randomization within 3 hours post-recanalization；\n* Informed consent signed by the patient or their legal representative.\n\nExclusion Criteria:\n\n* Pre-stroke mRS score \\> 1；\n* Comatose state (Glasgow Coma Scale \\[GCS\\] score \\\u003C 8);\n* Symptomatic intracerebral hemorrhage occurred before randomization;\n* Within the past 3 months, occurrence of acute ST-segment elevation myocardial infarction (MI), acute decompensated heart failure, QTc \\> 500 ms, hospitalization or involuntary coronary intervention due to acute coronary syndrome, MI, or cardiac arrest; or heart failure (New York Heart Association \\[NYHA\\] class III\u002FIV or left ventricular ejection fraction \\\u003C 35%); or known history of ventricular tachycardia;\n* History of severe renal insufficiency, acute renal failure, dialysis, or estimated glomerular filtration rate (eGFR) \\\u003C 20 ml\u002Fmin\u002F1.72m²;\n* History of severe hepatic disease, or Aspartate Aminotransferase (AST) and\u002For Alanine Aminotransferase (ALT) and\u002For Gamma-Glutamyl Transferase (GGT) ≥ 3×ULN and\u002For Total Bilirubin (TBIL) ≥ 2×ULN;\n* Aortic dissection, cervical artery dissection, or cerebral artery dissection; unruptured aortic aneurysm or cerebral aneurysm; or known arteriovenous malformation;\n* Comorbidities with a life expectancy \\\u003C 6 months (e.g., malignant tumors);\n* Pregnant or lactating women;\n* Participation in another clinical trial within the past 30 days;\n* Any clinical condition judged by the research team that might limit compliance with study procedures.","ALL","18 Years",{"count":20,"type":21},544,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The RESCUE-BP is a multi-centered, prospective, randomized, open label, blinded endpoint (PROBE) phase III trial. In patients with acute ischemic stroke who have undergone endovascular treatment and achieved successful recanalization, the evaluation will compare a stratified blood pressure management strategy based on the collateral circulation status with the guideline-recommended conventional blood pressure management strategy. Within each stratum, participants will be randomized in a 1:1 ratio to either the stratified blood pressure management strategy group or the guideline-recommended conventional blood pressure management group. The goal is to determine whether this can improve good functional outcomes at 90 days (90-day Modified Rankin Scale \\[mRS\\] score 0-2).\n\nThe study consists of four visits including the day of randomization, 24±4 hours after randomization, 7±1 days after randomization and 90±7 days after randomization. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment, neurological function rating scale will be recorded during the program.\n\nThe primary outcome is the modified Rankin Scale (mRS) score of 0 to 2 at 90±7 days after randomization. The primary safety outcome is the incidence of sICH within 24±4 hours after randomization.",[27,28,29,30,31],"Endovascular Therapy","Acute Ischaemic Stroke","Collateral Circulation","Blood Pressure Management","Prognosis","NOT_YET_RECRUITING","2026-04-17",{"date":35,"type":36},"2026-04-22","ACTUAL",{"date":38,"type":21},"2026-06-01",{"date":40,"type":21},"2028-02-29",{"name":42,"class":43},"Beijing Tiantan Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100619672","randomized-clinical-trial-of-endovascular-therapy-for-acute-ischemic-stroke-with-occlusion-of-the-m2-segment-of-middle-cerebral-artery-100619672","NCT07347665","Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery","Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery (the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-M2 Occlusion Trial: RESCUE-M2O Trial)","Inclusion Criteria:\n\n1. Acute cerebral infarction\n2. Aged 18-84 years\n3. NIHSS score at admission ≥ 8\n4. Prestroke mRS scores of 0-1 (able to carry out all usual activities)\n5. Occlusion of the M2 segment of MCA on digital subtraction angiography\n6. ASPECTS ≥ 8 or DWI-ASPECTS ≥ 8\n7. Ineligible or failed intravenous tPA (no recanalization within 30 min after injection)\n8. Randomization can be completed within 24 h from the last known well time\n9. EVT can be initiated within 30 min from randomization.\n10. The patient or their legally authorized representative has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Occlusion of the anterior temporal artery, duplicate M1, or accessory M1\n2. Occlusion of multiple major intracranial arteries\n3. Difficulty in endovascular access due to tortuous vascular anatomy\n4. Significant mass effect with midline shift on CT (or MRI)\n5. Known allergy (more severe than skin rash) to contrast agents\n6. Evidence of acute intracranial hemorrhage on CT (or MRI)\n7. Pregnant or potentially pregnant\n8. Clinical evidence of chronic occlusion\n9. High risk of hemorrhage (platelet \\\u003C 40,000\u002Ful, APTT \\> 50 sec or PT-INR \\> 3.0)\n10. Participating in any other therapeutic investigational trial\n11. Judgment of the investigator to be non-compliant or uncooperative during the study","84 Years",{"count":54,"type":21},200,[56],"NA","RESCUE-M2O trial is a prospective, open label, blinded endpoint (PROBE), two-arm, randomized, controlled, post-market study to assess the efficacy and safety of endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.",[27,59,60],"Acute Ischemic Stroke","Acute Ischemic Stroke (AIS) Related to a Distal Occlusion","RECRUITING","2026-02-22",{"date":64,"type":36},"2026-02-24",{"date":66,"type":36},"2025-12-01",{"date":68,"type":21},"2030-03-31",{"name":70,"class":43},"Hyogo Medical University",2,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":44},"100618617","the-efficacy-and-safety-of-endovascular-therapy-for-acute-ischemic-stroke-due-to-large-core-infarction-100618617","NCT07333950","The Efficacy and Safety of Endovascular Therapy for Acute Ischemic Stroke Due to Large Core Infarction","The Efficacy and Safety of Endovascular Therapy for Acute Ischemic Stroke Due to Large Core Infarction -- A Multicenter, Prospective, Open-label, Blind Endpoint, Randomized Controlled Trial","Inclusion Criteria:\n\n1. The age ranged from 18 to 80 years\n2. Acute ischemic stroke in posterior circulation, the time from stroke onset (or finally found normal) to randomization was within 24 hours\n3. Acute basilar artery occlusion confirmed by CTA,MRA,or DSA\n4. Posterior circulation large core infarction:NCCT or DWI showed pc-ASPECTS≤5, or Pons-Midbrain Index (PMI)≥3\n5. NIHSS score ≥10 before randomization\n6. Pre-stroke mRS of 0-2\n7. Each patient or their legal representative must provide written informed consent before enrolment\n\nExclusion Criteria:\n\n1. Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization\n2. Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging\n3. Known or highly suspected chronic occlusion of basilar artery\n4. History of contraindication for contrast medium (except mild rash)\n5. Current pregnant or breast-feeding\n6. Refractory hypertension (defined as systolic blood pressure\\>220 mmHg or diastolic blood pressure\\>110 mmHg) that cannot be controlled by drug treatment;\n7. Known to have dementia or psychiatric disease unable to complete neurological assessment and follow-up\n8. It is known that patients with dementia or mental illness cannot complete neurological function assessment and follow-up\n9. Patients whose life expectancy is less than 1 year (such as patients with malignant tumor, advanced cardiopulmonary disease, etc.)\n10. Enrolled in another drug or device trial or expected to participate in another drug or device treatment trial within the following 3 months\n11. Any other condition (in the opinion of the site investigator) that inappropriate to participate this study\n12. CTA\u002FMRA\u002FDSA confirmed occlusion of anterior and posterior circulation\n13. Central nervous system vasculitis has been diagnosed or clinically suspected\n14. Known hereditary or acquired bleeding tendency, lack of coagulation factors, or oral anticoagulants with INR\\>1.7\n15. Blood glucose\\\u003C2.7 or\\>22.2 mmol\u002FL; Platelet count\\\u003C50×109\u002FL, glomerular filtration rate\\\u003C30ml\u002Fmin or serum creatinine ≥ 3 mg\u002Fdl\n16. Acute cerebral infarction occurred within 48 hours after cardio cerebral vascular intervention or major surgery (patients over 48 hours can be included in the group)","80 Years",{"count":81,"type":21},308,[56],"This study assesses the efficacy and safety of endovascular therapy in patients with acute basilar artery occlusion with large core infarction within a multicenter, prospective, open-label, blinded endpoint, randomized controlled trial",[85,27,86],"Acute Basilar Artery Occlusion","Large Core Infarction",[88,85,27,86],"Ischemic Stroke","2025-12-30",{"date":91,"type":36},"2026-01-12",{"date":93,"type":21},"2026-01-01",{"date":95,"type":21},"2028-12-31",{"name":42,"class":43},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":104,"targetDuration":106,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":44},"100550808","early-identification-of-malignant-brain-edema-in-large-artery-occlusive-stroke-after-endovascular-therapy-embrace-study-100550808","NCT06451887","Early Identification of Malignant Brain Edema in laRge Artery oCclusive Stroke After Endovascular Therapy (EMBRACE Study)","EMBRACE","Inclusion Criteria:\n\n* (1)Age \\> 18 years old; (2)Onset of stroke to hospital admission \\\u003C 24 hours; (3)Admission with a head CT scan ruling out hemorrhage; (4)Patients undergoing CT perfusion scan before treatment; (5)Confirmation of internal carotid artery (ICA) or middle cerebral artery (MCA) occlusion or tandem occlusion by Digital Subtraction Angiography (DSA) and subsequent EVT; (6)complete 3-months follow-up.\n\nExclusion Criteria:\n\n* (1)Poor quality of preoperative CT perfusion imaging; (2)Posterior circulation occlusion or isolated anterior cerebral artery occlusion; (3)Presence of other severe diseases such as malignant tumors, severe organ failure, or other life-threatening conditions with an expected survival period of less than 90 days; (4)Incomplete imaging and clinical data.",{"count":105,"type":21},1950,"3 Months","OBSERVATIONAL","To design and validate a predictive model for malignant brain edema after endovascular thrombectomy.",[27,110,111,88],"Brain Edema","Prediction Model",[113,114,115,116],"Endovascular therapy","Brain edema","Prediction model","Ischemic stroke","2024-06-06",{"date":119,"type":36},"2024-06-11",{"date":121,"type":36},"2024-04-01",{"date":123,"type":21},"2027-06",{"name":125,"class":43},"Zhejiang Provincial People's Hospital"]